Drug Profile
Research programme: neurodegenerative disorders therapeutics - FORUM Pharmaceuticals
Alternative Names: EVP-0002442; EVP-2442; Neurodegenerative disorders therapeutics - EnVivoLatest Information Update: 10 Apr 2014
Price :
$50
*
At a glance
- Originator EnVivo Pharmaceuticals
- Developer CHDI; EnVivo Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurodegenerative disorders
Most Recent Events
- 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals
- 13 Feb 2008 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
- 30 Nov 2005 This research programme is available for licensing (http://www.envivopharma.com)